|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received September 28, 2007
Accepted on January 10, 2008
ORIGINAL ARTICLES |
,
*Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, and
Division of Nephrology, Hospital of Manduria, Manduria, Italy
1 To whom correspondence should be addressed. E-mail: basile.miulli{at}libero.it.
| Abstract |
|---|
Background and objectives: Vitamin D receptor activation by vitamin D sterols and calcium-sensing receptor stimulation by cinacalcet are the most powerful treatments of secondary hyperparathyroidism. This study was aimed to assess a possible association between histopathologic changes of parathyroid tissue and treatment modality.
Design, setting, participants, & measurements: Studies were performed on 82 parathyroids of 22 adult white hemodialysis patients undergoing first parathyroidectomy. The type of hyperplasia and the distribution of chief and oxyphil cells, expressed as oxyphil/chief cell ratio, were assessed. Three groups could be studied according to treatment modality: group A consisted of 6 patients who were treated with cinacalcet, intravenous calcitriol, and phosphate binders; group B consisted of 6 patients who were treated with intravenous calcitriol and phosphate binders, and group C consisted of 10 patients who were treated with phosphate binders alone.
Results: Sixty-eight (82.9%) out of 82 glands removed showed nodular hyperplasia. It was more frequent in groups A and B than in group C. A stepwise forward logistic regression model showed that the probability of nodular hyperplasia was higher in patients who were on calcitriol and/or cinacalcet therapy, in female gender and in patients with a higher body mass index. Oxyphil/chief cell ratio also was significantly different among the three groups. Cinacalcet treatment was the only predictor of this ratio.
Conclusions: An association was found between calcitriol and/or cinacalcet therapy and a high prevalence of nodular hyperplasia, and between cinacalcet therapy and high oxyphil/chief cell ratio. The meaning of the observed associations remains uncertain.
This article has been cited by other articles:
![]() |
H. Komaba and M. Fukagawa Regression of parathyroid hyperplasia by calcimimetics--fact or illusion? Nephrol. Dial. Transplant., March 1, 2009; 24(3): 707 - 709. [Full Text] [PDF] |
||||
![]() |
M. Meola, I. Petrucci, and G. Barsotti Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism Nephrol. Dial. Transplant., March 1, 2009; 24(3): 982 - 989. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Arcidiacono, M. Cozzolino, N. Spiegel, M. Tokumoto, J. Yang, Y. Lu, T. Sato, C. Lomonte, C. Basile, E. Slatopolsky, et al. Activator Protein 2{alpha} Mediates Parathyroid TGF-{alpha} Self-Induction in Secondary Hyperparathyroidism J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1919 - 1928. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, and M. Fukagawa Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism NDT Plus, August 1, 2008; 1(suppl_3): iii49 - iii53. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |